Biohaven [BHVN] vs Regeneron [REGN] Detailed Stock Comparison
Biohaven
NYSE
Loading...
Regeneron
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Biohaven wins in 3 metrics, Regeneron wins in 12 metrics, with 0 ties. Regeneron appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Biohaven | Regeneron | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -1.64 | 14.95 | Biohaven |
| Price-to-Book Ratio | 12.35 | 2.06 | Regeneron |
| Debt-to-Equity Ratio | 25.63 | 9.04 | Regeneron |
| PEG Ratio | 0.04 | 13.09 | Biohaven |
| EV/EBITDA | -1.39 | 12.21 | Biohaven |
| Profit Margin (TTM) | 0.00% | 31.37% | Regeneron |
| Operating Margin (TTM) | 0.00% | 29.64% | Regeneron |
| EBITDA Margin (TTM) | N/A | 29.64% | N/A |
| Return on Equity | -295.94% | 15.34% | Regeneron |
| Return on Assets (TTM) | -103.41% | 6.66% | Regeneron |
| Free Cash Flow (TTM) | $-586.50M | $3.54B | Regeneron |
| Dividend Yield | N/A | 0.46% | N/A |
| 1-Year Return | -64.82% | -50.12% | Regeneron |
| Price-to-Sales Ratio (TTM) | N/A | 4.42 | N/A |
| Enterprise Value | $1.29B | $54.52B | Regeneron |
| EV/Revenue Ratio | N/A | 3.84 | N/A |
| Gross Profit Margin (TTM) | N/A | 85.58% | N/A |
| Revenue per Share (TTM) | $0 | $133 | Regeneron |
| Earnings per Share (Diluted) | $-7.46 | $39.68 | Regeneron |
| Beta (Stock Volatility) | 3.50 | 0.33 | Regeneron |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Biohaven vs Regeneron Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Biohaven | -0.14% | 3.16% | 6.30% | -6.50% | -60.23% | -60.62% |
| Regeneron | 1.21% | 5.69% | 9.65% | -1.07% | -14.59% | -16.36% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Biohaven | -64.82% | 101.10% | 101.10% | -18.03% | -18.03% | -18.03% |
| Regeneron | -50.12% | 0.33% | -0.74% | 11.45% | 2,525.81% | 7,886.11% |
Performance & Financial Health Analysis: Biohaven vs Regeneron
| Metric | BHVN | REGN |
|---|---|---|
| Market Information | ||
| Market Cap | $1.66B | $62.88B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 1,885,210 | 859,422 |
| 90 Day Avg. Volume | 1,925,720 | 933,271 |
| Last Close | $14.68 | $598.16 |
| 52 Week Range | $12.79 - $55.70 | $476.49 - $1,211.20 |
| % from 52W High | -73.64% | -50.61% |
| All-Time High | $67.86 (Jun 03, 2019) | $1,211.20 (Aug 26, 2024) |
| % from All-Time High | -78.37% | -50.61% |
| Growth Metrics | ||
| Quarterly Revenue Growth | N/A | 0.04% |
| Quarterly Earnings Growth | N/A | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | 0.00% | 0.31% |
| Operating Margin (TTM) | 0.00% | 0.30% |
| Return on Equity (TTM) | -2.96% | 0.15% |
| Debt to Equity (MRQ) | 25.63 | 9.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $1.27 | $287.55 |
| Cash per Share (MRQ) | $3.83 | $72.04 |
| Operating Cash Flow (TTM) | $-645,078,016 | $4.74B |
| Levered Free Cash Flow (TTM) | $-508,353,632 | $2.85B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.46% |
| Last 12-Month Dividend | N/A | $2.64 |
Valuation & Enterprise Metrics Analysis: Biohaven vs Regeneron
| Metric | BHVN | REGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -1.64 | 14.95 |
| Forward P/E | -2.49 | 13.09 |
| PEG Ratio | 0.04 | 13.09 |
| Price to Sales (TTM) | N/A | 4.42 |
| Price to Book (MRQ) | 12.35 | 2.06 |
| Market Capitalization | ||
| Market Capitalization | $1.66B | $62.88B |
| Enterprise Value | $1.29B | $54.52B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | N/A | 3.84 |
| Enterprise to EBITDA | -1.39 | 12.21 |
| Risk & Other Metrics | ||
| Beta | 3.50 | 0.33 |
| Book Value per Share (MRQ) | $1.27 | $287.55 |
Financial Statements Comparison: Biohaven vs Regeneron
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BHVN | REGN |
|---|---|---|
| Revenue/Sales | $0 | $3.03B |
| Cost of Goods Sold | N/A | $464.30M |
| Gross Profit | N/A | $2.56B |
| Research & Development | $187.58M | $1.34B |
| Operating Income (EBIT) | $-221.56M | $591.70M |
| EBITDA | $-219.32M | $900.90M |
| Pre-Tax Income | $-221.07M | $905.00M |
| Income Tax | $609,000 | $96.30M |
| Net Income (Profit) | $-221.68M | $808.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BHVN | REGN |
|---|---|---|
| Cash & Equivalents | $98.42M | $3.09B |
| Total Current Assets | $382.76M | $17.57B |
| Total Current Liabilities | $164.03M | $3.57B |
| Long-Term Debt | $30.80M | $2.70B |
| Total Shareholders Equity | $259.50M | $29.39B |
| Retained Earnings | $-1.57B | $32.38B |
| Property, Plant & Equipment | $36.78M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BHVN | REGN |
|---|---|---|
| Operating Cash Flow | $-164.28M | $1.36B |
| Capital Expenditures | $-461,000 | N/A |
| Free Cash Flow | $-165.59M | $773.60M |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | $-1.05B |
Short Interest & Institutional Ownership Analysis
| Metric | BHVN | REGN |
|---|---|---|
| Shares Short | 12.71M | 2.29M |
| Short Ratio | 6.72 | 2.55 |
| Short % of Float | 0.14% | 0.02% |
| Average Daily Volume (10 Day) | 1,885,210 | 859,422 |
| Average Daily Volume (90 Day) | 1,925,720 | 933,271 |
| Shares Outstanding | 101.22M | 109.62M |
| Float Shares | 88.38M | 97.89M |
| % Held by Insiders | 0.12% | 0.02% |
| % Held by Institutions | 0.83% | 0.91% |
Dividend Analysis & Yield Comparison: Biohaven vs Regeneron
| Metric | BHVN | REGN |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.64 |
| Last 12-Month Dividend Yield | N/A | 0.46% |
| 3-Year Avg Annual Dividend | N/A | $0.88 |
| 3-Year Avg Dividend Yield | N/A | 0.14% |
| 3-Year Total Dividends | N/A | $2.64 |
| Ex-Dividend Date | N/A | Aug 18, 2025 |